Vanesa Quiroga

Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer

Charles E. Geyer, Judy E. Garber, Richard D. Gelber et al. · Annals of Oncology · 2022 · 447 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

BRCA1 mRNA expression and outcome to neoadjuvant cisplatin-based chemotherapy in bladder cancer

Albert Font, Miquel Tarón, J. Gago et al. · Annals of Oncology · 2010 · 137 citations · Full text

Medicine, Oncology, Urology +11

Second-line endocrine therapy (ET) with or without palbociclib (P) maintenance in patients (pts) with hormone receptor-positive (HR[+])/human epidermal growth factor receptor 2-negative (HER2[-]) advanced breast cancer (ABC): PALMIRA trial.

Antonio Llombart‐Cussac, Catherine Harper‐Wynne, Antonia Perelló et al. · Journal of Clinical Oncology · 2023 · 72 citations

Medicine, Oncology, Pharmacology +17

Palbociclib Rechallenge for Hormone Receptor–Positive/HER-Negative Advanced Breast Cancer: Findings from the Phase II BioPER Trial

Joan Albanell, José Manuel Pérez-García, Miguel Gil‐Gil et al. · Clinical Cancer Research · 2022 · 37 citations · Full text

Medicine, Oncology, Pharmacology +16

Whole exome sequencing identifies <i>PLEC</i>, <i>EXO5</i> and <i>DNAH7</i> as novel susceptibility genes in testicular cancer

Beatriz Paumard‐Hernández, Oriol Calvete, Lucía Inglada‐Pérez et al. · International Journal of Cancer · 2018 · 35 citations · Full text

Life Sciences, Genetics, Molecular Genetics +17